Tuberculosis Vaccines in Clinical Trials

Overview

Journal Expert Rev Vaccines

Date 2011 May 25

PMID 21604985

Citations 46

Authors

Rosalind Rowland

Helen McShane

Affiliations

Soon will be listed here.

Abstract

Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette-Guérin (BCG), suggests effective vaccination is possible and highlights the need for an improved vaccination strategy. Clinical trials are evaluating both modifications to the existing BCG immunization methods and also novel TB vaccines, designed to replace or boost BCG. Candidate vaccines in clinical development include live mycobacterial vaccines designed to replace BCG, subunit vaccines designed to boost BCG and therapeutic vaccines designed as an adjunct to chemotherapy. There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen.

Citing Articles

Trends in Viral Vector-Based Vaccines for Tuberculosis: A Patent Review (2010-2023).

Santos L, Fernandes A, Alves I, Serafini M, Silva L, Fonseca de Freitas H Vaccines (Basel). 2024; 12(8).

PMID: 39204002 PMC: 11359462. DOI: 10.3390/vaccines12080876.

The whole genome sequence of Polish vaccine strain BCG Moreau.

Krysztopa-Grzybowska K, Lach J, Polak M, Strapagiel D, Dziadek J, Olszewski M Microbiol Spectr. 2024; 12(7):e0425923.

PMID: 38757975 PMC: 11237378. DOI: 10.1128/spectrum.04259-23.

Efficacy of light chain 3-fused protein multi epitope in protection of mice challenged with .

Bahrami S, Feizabadi M, Mosavari N, Sotoodehnejad F, Eslampanah M Vet Res Forum. 2024; 14(12):659-664.

PMID: 38174093 PMC: 10759770. DOI: 10.30466/vrf.2023.1975747.3702.

Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China.

Li J, Lu J, Wang G, Zhao A, Xu M Vaccines (Basel). 2022; 10(7).

PMID: 35891320 PMC: 9320669. DOI: 10.3390/vaccines10071157.

Controlled Human Infection Models To Accelerate Vaccine Development.

Choy R, Louis Bourgeois A, Ockenhouse C, Walker R, Sheets R, Flores J Clin Microbiol Rev. 2022; 35(3):e0000821.

PMID: 35862754 PMC: 9491212. DOI: 10.1128/cmr.00008-21.

References

Rodrigues L, Diwan V, Wheeler J . Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993; 22(6):1154-8. DOI: 10.1093/ije/22.6.1154. View

Diness B, Fisker A, Roth A, Yazdanbakhsh M, Sartono E, Whittle H . Effect of high-dose vitamin A supplementation on the immune response to Bacille Calmette-Guerin vaccine. Am J Clin Nutr. 2007; 86(4):1152-9. DOI: 10.1093/ajcn/86.4.1152. View

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Eddine A . Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest. 2005; 115(9):2472-9. PMC: 1187936. DOI: 10.1172/JCI24617. View

Cooper A . Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009; 27:393-422. PMC: 4298253. DOI: 10.1146/annurev.immunol.021908.132703. View

Agger E, Rosenkrands I, Olsen A, Hatch G, Williams A, Kritsch C . Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine. 2006; 24(26):5452-60. DOI: 10.1016/j.vaccine.2006.03.072. View

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schatzl H . Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses. 2007; 23(6):782-93. DOI: 10.1089/aid.2006.0226. View

Ottenhoff T, Kumararatne D, Casanova J . Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today. 1998; 19(11):491-4. DOI: 10.1016/s0167-5699(98)01321-8. View

Larsen M, Biermann K, Chen B, Hsu T, Sambandamurthy V, Lackner A . Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine. 2009; 27(34):4709-17. PMC: 3512200. DOI: 10.1016/j.vaccine.2009.05.050. View

10.

Sambandamurthy V, Derrick S, Jalapathy K, Chen B, Russell R, Morris S . Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun. 2005; 73(2):1196-203. PMC: 547051. DOI: 10.1128/IAI.73.2.1196-1203.2005. View

11.

Johnson J, Kamya R, Okwera A, Loughlin A, Nyole S, Hom D . Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J Infect Dis. 2000; 181(4):1304-12. DOI: 10.1086/315393. View

12.

Hesseling A, Marais B, Gie R, Schaaf H, Fine P, Godfrey-Faussett P . The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine. 2006; 25(1):14-8. DOI: 10.1016/j.vaccine.2006.07.020. View

13.

Crampin A, Glynn J, Fine P . What has Karonga taught us? Tuberculosis studied over three decades. Int J Tuberc Lung Dis. 2009; 13(2):153-64. PMC: 3272402. View

14.

Reed S, Coler R, Dalemans W, Dalemans W, Tan E, Dela Cruz E . Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A. 2009; 106(7):2301-6. PMC: 2650151. DOI: 10.1073/pnas.0712077106. View

15.

Aronson N, Santosham M, Comstock G, Howard R, Moulton L, Rhoades E . Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA. 2004; 291(17):2086-91. DOI: 10.1001/jama.291.17.2086. View

16.

Barouch D, Pau M, Custers J, Koudstaal W, Kostense S, Havenga M . Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004; 172(10):6290-7. DOI: 10.4049/jimmunol.172.10.6290. View

17.

Williams A, Goonetilleke N, McShane H, Clark S, Hatch G, Gilbert S . Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun. 2005; 73(6):3814-6. PMC: 1111825. DOI: 10.1128/IAI.73.6.3814-3816.2005. View

18.

Williams A, Hatch G, Clark S, Gooch K, Hatch K, Hall G . Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb). 2005; 85(1-2):29-38. DOI: 10.1016/j.tube.2004.09.009. View

19.

Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas M, Nouze C . High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun. 2006; 74(6):3396-407. PMC: 1479244. DOI: 10.1128/IAI.02086-05. View

20.

Dietrich J, Aagaard C, Leah R, Olsen A, Stryhn A, Doherty T . Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol. 2005; 174(10):6332-9. DOI: 10.4049/jimmunol.174.10.6332. View